{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for folic root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01445899: Phase 2 Interventional Completed Choroidal Neovascularization
(2012)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01743807: Phase 1 Interventional Terminated Relapsed Acute Lymphoblastic Leukemia
(2014)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00002403: Phase 1 Interventional Completed HIV Infections
Source URL:
Class:
NUCLEIC ACID
Status:
Designated
Source:
EU-Orphan Drug:EU/3/19/2171
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
NUCLEIC ACID
